NovaBay Pharmaceuticals

EMERYVILLE, CA · Biotech · Public

Auriclosene, a topical anti-infective compound for treating diabetic foot ulcers and managing infected wounds

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · novabaypharma.com

Sector: Biotech
Headquarters: EMERYVILLE, CA
Latest Form D: $134M, Jan 2026
Total capital: $200M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $200M; 18 Form D · last Jan 2026; 9 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 22 pending · first 2014; Rank in peer group#397 of 1449

Capital timeline

Latest events

Jan 2026Private capital raisedForm D · SEC · 17th filing$134M
Jun 2024Private capital raisedForm D · SEC · 16th filing$226K
Apr 2024Private capital raisedForm D · SEC · 15th filing$665K
Jan 2024Private capital raisedForm D · SEC · 14th filing$555K
May 2023Private capital raisedForm D · SEC · 13th filing$3M
Sep 2022Private capital raisedForm D · SEC · 12th filing$3.3M
Sep 2022Private capital raisedForm D · SEC · 11th filing$2.1M
Nov 2021Private capital raisedForm D · SEC · 10th filing$15M
Jul 2020Offering registeredForm D · SEC · 9th filing$6.8M
May 2020Private capital raisedForm D · SEC · 8th filing$1K
Aug 2019Private capital raisedForm D · SEC · 7th filing$2.7M
Aug 2019Private capital raisedForm D · SEC · 6th filing$4.2M
Jul 2019Private capital raisedForm D · SEC · 5th filing$2.4M
Feb 2018Private capital raisedForm D · SEC · 4th filing$6M
May 2016Private capital raisedForm D · SEC · 3rd filing$7.8M
Feb 2016Private capital raisedForm D · SEC · 2nd filing$2.8M
Mar 2015Private capital raisedForm D · SEC · 1st filing$15.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

ANDREW JONESExecutive OfficerNamed in SEC Form D filings
AUDREY KUNINExecutive Officer, DirectorNamed in SEC Form D filings
Charles CashionDirectorNamed in SEC Form D filings
GAIL MADERISDirectorNamed in SEC Form D filings
JASON RALEIGHExecutive OfficerNamed in SEC Form D filings
JEFFREY KUNINExecutive OfficerNamed in SEC Form D filings

Show all 33 people

John J. McGovernExecutive OfficerNamed in SEC Form D filings
JULIE GARLIKOVDirectorNamed in SEC Form D filings
JUSTIN HALLExecutive OfficerNamed in SEC Form D filings
Lewis J. StuartExecutive OfficerNamed in SEC Form D filings
LYNN CHRISTOPHERExecutive OfficerNamed in SEC Form D filings
Mark M. SieczkarekExecutive Officer, DirectorNamed in SEC Form D filings
Massimo E. RadaelliDirectorNamed in SEC Form D filings
Michael John KazleyExecutive Officer, DirectorNamed in SEC Form D filings
MIJIA (BOB) WUDirectorNamed in SEC Form D filings
Mijia Alex WuDirectorNamed in SEC Form D filings
PAUL E. FREIMANDirectorNamed in SEC Form D filings
Ramin (Ron) NajafiExecutive Officer, DirectorNamed in SEC Form D filings
Roy J. WuExecutive OfficerNamed in SEC Form D filings
SWAN SITDirectorNamed in SEC Form D filings
T. Alex E. McPhersonDirectorNamed in SEC Form D filings
Thomas J. PaulsonExecutive OfficerNamed in SEC Form D filings
T. Alex McPhersonDirectorNamed in SEC Form D filings
TODD ZAVODNICKDirectorNamed in SEC Form D filings
TOMMY LAWExecutive OfficerNamed in SEC Form D filings
Tony E. WicksDirectorNamed in SEC Form D filings
XIAOPEI (RAY) WANGDirectorNamed in SEC Form D filings
Xiaoyan (Henry) J. LiuDirectorNamed in SEC Form D filings
Xiaoyan Alex LiuDirectorNamed in SEC Form D filings
XINZHOU (PAUL) LIDirectorNamed in SEC Form D filings
YENYOU (JEFF) ZHENGDirectorNamed in SEC Form D filings
Yonghao (Carl) J. MaDirectorNamed in SEC Form D filings
YONGXIANG (SEAN) ZHENGDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 24

Apr 18, 2017GrantedContact Lens Cleaning System With InsulationUSPTOUS 9,625,744
Feb 23, 2017PendingMagnetic Valve SystemUSPTOApplication 14831620
Dec 1, 2016PendingMethod of Inactivating Bacterial Lipases Using Oxidative Chlorine SpeciesUSPTOApplication 15167435

Show all 24 patent records

Contact Lens Cleaning System With InsulationApr 18, 2017 · US 9,625,744Granted
Magnetic Valve SystemFeb 23, 2017 · Application 14831620Pending
Method of Inactivating Bacterial Lipases Using Oxidative Chlorine SpeciesDec 1, 2016 · Application 15167435Pending
Method Of Inactivating Toxins Using Oxidative Chlorine SpeciesNov 17, 2016 · Application 15151344Pending
Contact Lens Cleaning System With MonitorJan 8, 2015 · Application 14475179Pending
Antimicrobial Haloalkyl Heterocycle CompoundsMay 20, 2014 · US 8,729,112Granted
Contact Lens Cleaning System With MonitorApplication PCTUS2012026249Pending
Polysaccharide Based Antimicrobial FormulationsApplication PCTUS2011023513Pending
Methods Of Treating Infections Of The Nail Or Skin Using HypohaliteApplication PCTUS2010043261Pending
Methods Of Treating Infections Of The NailApplication PCTUS2010032277Pending
Antimicrobial N-chlorinated CompositionsApplication PCTUS2009063652Pending
Antimicrobial Oxazolidinone, Hydantoin And Imidazolidinone CompositionsApplication PCTUS2009063302Pending
Antimicrobial Gel FormulationsApplication PCTUS2009053625Pending
Compositions And Methods For Treatment And Prophylaxis Of Bronchopulmonary InfectionsApplication PCTUS2009040251Pending
N-halogenated Amino Compounds And DerivativesApplication PCTUS2007089143Pending
Method For Treatment Of Wound Using AganocidesApplication PCTUS2007071263Pending
System And Method For The Prevention Of Bacterial And Fungal Infections Including Urinary Tract Infections (uti) Using N-halogenated Amino AcidsApplication PCTUS2006039216Pending
System And Method For The Prevention And Treatment Of Bacterial And Fungal Infections Including Urinary Tract Infections (uti) Using A Hypohalous AcidApplication PCTUS2006036968Pending
N-halogenated Amino Acids, N,n-dihalogenated Amino Acids And Derivatives; Compositions And Methods Of Using ThemApplication PCTUS2006002875Pending
Method Of Inactivating Bacterial Lipases Using Oxidative Chlorine SpeciesApplication PCTUS2016034753Pending
Method Of Inactivating Toxing Oxidative Chlorine SpeciesApplication PCTUS2016031659Pending
Method Of Inactivating Bacterial Lipases Using Oxidative Chlorine SpeciesApplication 62168666Pending
Contact Lens Cleaning System With InsulationApplication PCTUS2014063579Pending
Enhanced Contact Lens Cleaning and Disinfection SystemApplication 61897978Pending

Renibus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Candid TherapeuticsSimilar federal contract value in Biotech · null in contracts
Revolution MedicinesSimilar federal contract value in Biotech · null in contracts
TrueBinding, Inc.Similar federal contract value in Biotech · null in contracts
Bright Peak TherapeuticsSimilar federal contract value in Biotech · null in contracts
Cognito Therapeutics Group, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.